Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Cancer immunotherapy in 2017

The breakthrough of the microbiota

Nature Reviews Immunology volume 18, pages 87–88 (2018)Cite this article

Subjects

In 2017, epidemiological studies in humans and experiments in mouse models showed that the intestinal microbiota determines the effectiveness of anticancer immunotherapies. As such the microbiota offers new prognostic biomarkers and shows promise as a target for future antineoplastic treatments.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Impact of bacteria on immuno-oncology.

References

  1. Geva-Zatorsky, N. et al. Mining the human gut microbiota for immunomodulatory organisms. Cell 168, 928–943 (2017).

    Article  CAS  PubMed  Google Scholar 

  2. Haber, A. L. et al. A single-cell survey of the small intestinal epithelium. Nature 551, 333–339 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Peled, J. U. et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J. Clin. Oncol. 35, 1650–1659 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).

    Article  CAS  PubMed  Google Scholar 

  8. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).

    Article  CAS  PubMed  Google Scholar 

  9. Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Zitvogel, L. et al. Anticancer effects of the microbiome and its products. Nat. Rev. Microbiol. 15, 465–478 (2017).

    Article  CAS  PubMed  Google Scholar 

  11. Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors are supported by grants from the Institut National contre le Cancer, Ligue Nationale contre le Cancer, Swiss Bridge Foundation, ISREC, RHU-TORINO-LUMIERE, SIRIC Socrates at Gustave Roussy and Seerave Foundation.

Author information

Authors and Affiliations

  1. Department of Women's and Children's Health, Guido Kroemer is at Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers; Paris, France; Cell Biology and Metabolomics platforms, Gustave Roussy Cancer Campus; Villejuif, France; INSERM U1138, Paris, France; Université Paris Descartes, Sorbonne Paris Cité; Paris, France; Université Pierre et Marie Curie, Paris, France; Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France; and Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.,

    Guido Kroemer

  2. Paris, France,

    Guido Kroemer

  3. Laurence Zitvogel is at INSERM U1015, labellisée Ligue Française Contre le Cancer, Université Paris-Saclay, Gustave Roussy Immuno-Oncology Programme, Paris, France.,

    Laurence Zitvogel

Authors
  1. Guido Kroemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence Zitvogel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Guido Kroemer or Laurence Zitvogel.

Ethics declarations

Competing interests

G.K and L.Z. are co-founders of everImmune, a biotech company that identifies bacteria for cancer treatment.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kroemer, G., Zitvogel, L. The breakthrough of the microbiota. Nat Rev Immunol 18, 87–88 (2018). https://doi.org/10.1038/nri.2018.4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nri.2018.4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing